Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 61, Issue , 2012, Pages 86-92

  Wang, Ling Zhi ^a   Ong, Rina Yue Ling ^b   Chin, Tan Min ^a,c   Thuya, Win Lwin ^a   Wan, Seow Ching ^a   Wong, Andrea Li Ann ^c   Chan, Sui Yung ^b   Ho, Paul C ^b   Goh, Boon Cher ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Human blood; Hydroxychloroquine; LC MS MS; Quantification; Rapid

Indexed keywords

GEFITINIB; HYDROXYCHLOROQUINE SULFATE;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; DRUG MONITORING; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, LIQUID; HUMANS; HYDROXYCHLOROQUINE; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 84856079411     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.11.034     Document Type: Article

References (25)

1. Lacy C.F., Armstrong L.L. Drug Information Handbook with International Trade Names Index 2010, Lexicomp, pp. 818-820. 19th ed.
2. Micromedex® Healthcare Series. Available from: http://www.thomsonhc.com.libproxy1.nus.edu.sg/hcs/librarian/ND_T/HCS/ND_PR/Main/CS/F31D18/DUPLICATIONSHIELDSYNC/087B62/ND_PG/PRIH/ND_B/HCS/SBK/3/ND_P/Main/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/2557/ContentSetId/31%23adultDosageSection.
3. National University Hospital (NUH), Massachusetts General Hospital (MGH), AstraZeneca, Hydroxychloroquine and Gefitinib to treat Lung Cancer, 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00809237.
4. Swaisland H.C., Cantarini M.V., Fuhr R., Holt A. Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. Clin. Pharmacokinet. 2006, 45:633-644.
5. McKillop D., McCormick A.D., Millar A., Miles G.S., Phillips P.J., Hutchison M. Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica 2005, 35:39-50.
6. McKillop D., McCormick A.D., Miles G.S., Phillips P.J., Pickup K.J., Bushby N., Hutchison M. In vitro metabolism of gefitinib in human liver microsomes. Xenobiotica 2004, 34:983-1000.
7. Li J., Zhao M., He P., Hidalgo M., Baker S.D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin. Cancer Res. 2007, 13:3731-3737.
8. Munster T., Gibbs J.P., Shen D., Baethge B.A., Botstein G.R., Caldwell J., Dietz F., Ettlinger R., Golden H.E., Lindsley H., McLaughlin G.E., Moreland L.W., Roberts W.N., Rooney T.W., Rothschild B., Sack M., Sebba A.I., Weisman M., Welch K.E., Yocum D., Furst D.E. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002, 46:1460-1469.
9. Carmichael S.J., Charles B., Tett S.E. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther. Drug Monit. 2003, 25:671-681.
10. Miller D.R., Fiechtner J.J., Carpenter J.R., Brown R.R., Stroshane R.M., Stecher V.J. Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis. Arthritis Rheum. 1987, 30:567-571.
11. Costedoat-Chalumeau N., Amoura Z., Hulot J.S., Aymard G., Leroux G., Marra D., Lechat P., Piette J.C. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann. Rheum. Dis. 2007, 66:821-824.
12. Costedoat-Chalumeau N., Amoura Z., Hulot J.S., Hammoud H.A., Aymard G., Cacoub P., Francès C., Wechsler B., Huong du L.T., Ghillani P., Musset L., Lechat P., Piette J.C. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006, 54:3284-3290.
13. Lim H.S., Im J.S., Cho J.Y., Bae K.S., Klein T.A., Yeom J.S., Kim T.S., Choi J.S., Jang I.J., Park J.W. Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax. Antimicrob. Agents Chemother. 2009, 53:1468-1475.
14. Tett S.E., Cutler D.J., Day R.O., Brown K.F. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br. J. Clin. Pharmacol. 1989, 27:771-779.
15. Somer M., Kallio J., Pesonen U., Pyykkö K., Huupponen R., Scheinin M. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br. J. Clin. Pharmacol. 2000, 49:549-554.
16. Swaisland H.C., Ranson M., Smith R.P., Leadbetter J., Laight A., McKillop D., Wild M.J. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin. Pharmacokinet. 2005, 44:1067-1081.
17. Brown R.R., Stroshane R.M., Benziger D.P. High-performance liquid chromatographic assay for hydroxychloroquine and three of its major metabolites, desethylhydroxychloroquine, desethylchloroquine and bidesethylchloroquine, in human plasma. J. Chromatogr. 1986, 377:454-459.
18. Tett S.E., Cutler D.J., Brown K.F. High performance liquid chromatographic assay for hydroxychloroquine and metabolites in blood and plasma, using a stationary phase of poly (styrenedivinylbenzene) and a mobile phase at pH 11, with fluorimetric detection. J. Chromatogr. 1985, 344:241-248.
19. Guidance for Industry, Bioanalytical Method Validation. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.
20. Wang L.Z., Lee L.S.U., Thuya W.L., Soon G.H., Kong L.R., Nye P.L., Lee E.J.D., Flexner C., Goh B.C. Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric method. J. Chromatogr. B 2011, 46:202-208.
21. Wang L.Z., Lim M.Y., Chin T.M., Thuya W.L., Nye P.L., Wong A., Chan S.Y., Goh B.C., Ho P.C. Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry. J. Mass Spectrom. 2011, 879:2155-2161.
22. Polson C., Sarkar P., Incledon B., Raguvaran V., Grant R. Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2003, 785:263-275.
23. Josefsson M., Rydberg I. Determination of methylphenidate and ritalinic acid in blood, plasma and oral fluid from adolescents and adults using protein precipitation and liquid chromatography tandem mass spectrometry-a method applied on clinical and forensic investigations. J. Pharm. Biomed. Anal. 2011, 55:1050-1059.
24. Manoa N., Satoa M., Nozawab M., Matsumotoa Y., Moria M., Yamaguchia H., Gotoa J., Shimadaa M. An accurate quantitative LC/ESI-MS/MS method for sirolimus in human whole blood. J. Chromatogr. B 2011, 879:987-992.
25. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 2003, 75:3019-3030.